IKT-001 enters Phase 3 in PAH fully funded to readout, but efficacy in humans is unproven — enrollment pace and Part A PVR signal are the first tests

Updated 35d ago

Inhibikase Therapeutics is a clinical-stage company developing a targeted drug for pulmonary arterial hypertension that is not yet approved.

IKT-001, a kinase inhibitor targeting pulmonary arterial hypertension, launched its registrational IMPROVE-PAH Phase 3 in April 2026 with no prior efficacy data in humans. The $209 million cash position is stated to cover operations through Part B topline data, making the thesis conditional on that readout demonstrating benefit on the six-minute walk distance primary endpoint. The novel two-part adaptive design, with Part A using a pulmonary vascular resistance surrogate, introduces regulatory uncertainty if the endpoints diverge.

Status

Intact

Conviction

Current Thesis Drivers

Phase 3 IMPROVE-PAH enrolling: 43 sites, 26 countries
$209M cash stated to fund through Part B readout
FDA Orphan Drug Designation granted July 2026
No human efficacy data reported prior to Phase 3

What could change the thesis?

Part A PVR readout: signal supports advancement vs. futility stops program
Part B 6MWD readout: positive confirms efficacy, miss ends registration path
Warrant exercise assumption: full exercise funds runway, shortfall forces dilutive raise

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

1 programs · 3 catalysts

Stress Test